feed,title,long_url,short_url
Benzinga,Gilead Analysts Dissect Immunomedics Deal: 'Pricier But Bold Move Into Oncology',https://www.benzinga.com/analyst-ratings/analyst-color/20/09/17490141/gilead-analysts-dissect-immunomedics-deal-pricier-but-bold-move-into-oncology,https://j.mp/3kl3ryZ
